(English) GVB Biopharma Begins Cannabigerol (CBG) Studies to Assess Therapeutic Potential

LAS VEGAS, Aug. 6, 2020 /PRNewswire/ — GVB Biopharma, a pharmaceutical company specializing in hemp and cannabis-related consumer products, announced today that it has established the process and infrastructure for producing medicinal products from cannabigerol (CBG). This natural cannabinoid is a critical precursor molecule to two well-known cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD).